Kevin Noonan, Jun 27, 2012
The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding generic drugs. This threat is posed by the practice of “reverse payments” in ANDA litigation. Typically, in these arrangements a branded drug manufacturer settles litigation with a generic challenger brought under the Hatch-Waxman Act and such settlements often involve a payment from the branded to the generic drug maker.
In the FTCR
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.225.255.134
Please verify email or join us to access premium content!